Erminia Guarneri
Cardiovascular Disease · la Jolla, CANPI 1013024868
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 70 payments — averaging $22.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$349
- Exact Sciences$180
- Pfizer$129
- Esperion Therapeutics, Inc.$124
- Boehringer Ingelheim$102
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$92
- plus $577 from 15 others
What the payments were for
- Food & beverage$1,552100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $349 |
| Exact Sciences | 7 | $180 |
| Pfizer | 6 | $129 |
| Esperion Therapeutics, Inc. | 6 | $124 |
| Boehringer Ingelheim | 4 | $102 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $92 |
| AstraZeneca | 5 | $85 |
| Novo Nordisk | 3 | $66 |
| Amgen | 3 | $64 |
| Lilly USA, LLC | 2 | $51 |
| Boston Scientific | 2 | $47 |
| Cleerly, Inc. | 2 | $44 |
| Baxter Healthcare | 2 | $44 |
| Vifor Pharma, Inc. | 1 | $27 |
| Itamar Medical Inc | 2 | $27 |
| Irhythm Technologies, Inc. | 1 | $26 |
| Lucid Diagnostics Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
How this compares
$1,552 in reported general payments places this provider in the 40th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 37 | $50,804 |
| JardianceEmpagliflozin | 34 | $40,190 |
| MounjaroTirzepatide | 15 | $15,781 |
| TrulicityDulaglutide | 11 | $10,202 |
| Repatha SureclickEvolocumab | 12 | $6,385 |
| Ezetimibe | 72 | $2,680 |
| Valsartan | 21 | $1,555 |
| Rosuvastatin Calcium | 82 | $1,555 |
| Nebivolol Hcl | 11 | $822 |
| Levothyroxine Sodium | 60 | $751 |
| Losartan Potassium | 46 | $589 |
| Metoprolol Succinate | 33 | $568 |
| Escitalopram Oxalate | 16 | $432 |
| Amlodipine Besylate | 56 | $380 |
| ClopidogrelClopidogrel Bisulfate | 24 | $365 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $129 | $50,80437 claims |
| Boehringer IngelheimJardiance | $102 | $40,19034 claims |
| Lilly USA, LLCMounjaro, Trulicity | $51 | $25,98326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in la Jolla
- Eric Topolla Jolla$2.2M
- Pam Taubla Jolla$1.2M
- Douglas Gibsonla Jolla$727K
- Douglas Triffonla Jolla$176K
- Judith Swainla Jolla$151K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.